Effet de la thérapie à haut débit dans l'oxygénothérapie à long terme (HILOT)
Effet de la thérapie à haut débit dans l'oxygénothérapie à long terme (HILOT) : un essai clinique randomisé multicentrique basé sur un registre
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.
The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Magnus Ekström, MD, PhD
- Numéro de téléphone: +46 0455731000
- E-mail: magnus.ekstrom@med.lu.se
Lieux d'étude
-
-
-
Örebro, Suède, 70185
- Recrutement
- Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
-
Contact:
- Josefin Sundh, MD, PhD
-
-
Blekinge County
-
Karlskrona, Blekinge County, Suède, 37185
- Recrutement
- Research Unit, Blekinge University of Technology
-
Contact:
- Magnus Ekström, MD, PhD
- E-mail: magnus.ekstrom@med.lu.se
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 40 years or older
- Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
- COPD or ILD as main underlying reason for LTOT
- Oxygen concentrator as stationary oxygen source in the home including night-time
- Body mass index (BMI) < 35 kg/m2
Exclusion Criteria:
- Current or previous treatment with home HFOT
- Current treatment with home mechanical ventilation
- Current treatment with home CPAP
- Hospitalized during the last 2 weeks
- Current smoking or contact with flames
- Self-reported average use of the LTOT < 15h per day (24 hours)
- PaCO2 (breathing air at rest) > 8 kPa
- Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
- Inability to participate in the study procedures (as judged by the staff)
- Not eligible for continuing LTOT due to other reason (as judged by the staff)
- Expected survival less than 3 months (as judged by the staff)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: High-flow oxygen therapy
Intervention arm |
Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time. |
|
Comparateur actif: Low-flow oxygen therapy
Comparison arm |
Standard care with low-flow oxygen therapy in accordance with clinical routine. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to first hospitalization or death from all causes
Délai: 1 year
|
Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data) |
1 year
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to first all-cause hospitalization or all-cause death
Délai: 1 year
|
Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data) |
1 year
|
|
Rate of hospitalizations or death from all causes
Délai: 1 year
|
Rate of hospitalizations or death from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from all causes
Délai: 1 year
|
Hospitalization rate from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from respiratory disease
Délai: 1 year
|
Hospitalization rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Number of hospitalized days
Délai: 1 year
|
Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data |
1 year
|
|
Hospitalization rate from cardiovascular disease
Délai: 1 year
|
Hospitalization rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Number of admissions to intensive care unit (ICU)
Délai: 1 year
|
Number of admissions to ICU assessed using nationwide registry data |
1 year
|
|
Number of days in ICU
Délai: 1 year
|
Number of days in ICU assessed using nationwide registry data |
1 year
|
|
Mortality rate from all causes
Délai: 1 year
|
The mortality rate from all causes assessed using nationwide registry data |
1 year
|
|
Mortality rate from respiratory disease
Délai: 1 year
|
The mortality rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Mortality rate from cardiovascular disease
Délai: 1 year
|
The mortality rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Time to first exacerbation
Délai: 1 year
|
Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data |
1 year
|
|
Number of exacerbations
Délai: 1 year
|
Number of exacerbations of all severity assessed using self-reported and registry data |
1 year
|
|
Incidence of cardiovascular disease
Délai: 1 year
|
Incidence of cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Need for home mechanical ventilation
Délai: 1 year
|
Need for starting home mechanical ventilation assessed using nationwide registry data |
1 year
|
|
Rate of withdrawal of long-term oxygen therapy
Délai: 1 year
|
Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data |
1 year
|
|
Adverse events
Délai: 3 and 12 months
|
Self-reported adverse events since study start assessed using a postal questionnaire. |
3 and 12 months
|
|
Primary care utilization
Délai: 1 year
|
Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire. |
1 year
|
|
Health-related quality of life
Délai: 3 and 12 months
|
Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire. |
3 and 12 months
|
|
Health status
Délai: 3 and 12 months
|
Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire. |
3 and 12 months
|
|
Breathlessness at exertion
Délai: 3 and 12 months
|
Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire. |
3 and 12 months
|
|
Breathlessness
Délai: 3 and 12 months
|
Self-reported breathlessness assessed using the Dyspnea-12 questionnaire. |
3 and 12 months
|
|
Sleep quality
Délai: 3 and 12 months
|
Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire. |
3 and 12 months
|
|
Physical activity
Délai: 3 and 12 months
|
Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire. |
3 and 12 months
|
|
Change in health status
Délai: 3 and 12 months
|
Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale. |
3 and 12 months
|
|
Nasal symptoms
Délai: 3 and 12 months
|
Self-reported nasal symptoms assessed using the modified Björklund questionnaire. |
3 and 12 months
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient preference for continuing the treatment
Délai: 3 and 12 months
|
Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire. |
3 and 12 months
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Magnus Ekström, MD, PhD, Skane University Hospital
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- HILOT
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .